Quarterly ResultMay 7, 2026, 04:45 PM
Structure Therapeutics Reports Strong Q1, Aleniglipron Phase 3 On Track
AI Summary
Structure Therapeutics Inc. reported its first quarter 2026 financial results and provided a comprehensive business update. The company announced positive Phase 2 ACCESS II study results for aleniglipron, an oral GLP-1RA, showing up to 16.3% body weight loss at 44 weeks, and confirmed positive end-of-Phase 2 FDA feedback, with Phase 3 initiation on track for Q3 2026. Additionally, the company amended its ATM sales agreement, increasing the aggregate offering price of American Depositary Shares by $150 million to $400 million, and reported a strong cash position of $1.5 billion, providing a cash runway through the end of 2028.
Key Highlights
- Aleniglipron Phase 2 ACCESS II study demonstrated 16.3% mean body weight loss at 44 weeks.
- FDA provided positive end-of-Phase 2 feedback; aleniglipron Phase 3 initiation is on track for Q3 2026.
- Amended ATM sales agreement increased offering capacity by $150 million, for an aggregate of up to $400 million.
- Cash, cash equivalents, and short-term investments totaled $1.5 billion as of March 31, 2026.
- Cash runway is expected through the end of 2028, including Phase 3 registrational studies.
- Q1 2026 net loss was $76.0 million, compared to $46.8 million for the same period in 2025.
- Q1 2026 R&D expenses increased to $66.5 million from $42.9 million in Q1 2025.
- Previously sold 3,040,000 ATM Shares for gross proceeds of approximately $58.52 million.